MARKET OUTLOOKMylan’s salmeterol/fluticasone propionate generic, Wixela Inhub, is the first substitutable generic for GSK’s Advair, one of the top-selling therapies for asthma and COPD…
Insomnia is a highly prevalent sleep disorder characterized by daytime dysfunction resulting from sleep problems. The treatment of insomnia is highly individualized, and physicians consider…
Research on the human microbiome is beginning to mature, with microbiome-based therapies reaching the clinical trial phase of development for many disease areas. There have been significant…
Retinal vein occlusion (RVO) is a major cause of blindness, and affected approximately 1.6 million patients in 2018 in the United States. Patients are segmented by the anatomic location of the…
Retinal vein occlusion (RVO) is a major cause of blindness, and affected approximately 1.6 million patients in 2018 in the United States. Patients are segmented by the anatomic location of the…
Atopic dermatitis (AD) disproportionately affects children and adolescents, and its intermittent flares of itchy rash profoundly affect their quality of life. Most pediatric patients use prescribed…
Following the 2017 launches of two atopic dermatitis novel therapies, Pfizer’s topical PDE-4 inhibitor Eucrisa (crisaborole) and Sanofi/Regeneron’s IL-4/13 inhibitor Dupixent (dupilumab), the U…
Following the 2017 launches of two atopic dermatitis novel therapies, Pfizer’s topical PDE-4 inhibitor Eucrisa (crisaborole) and Sanofi/Regeneron’s IL-4/13 inhibitor Dupixent (dupilumab), the U…
DRG Epidemiology’s coverage of hepatitis B virus (HBV) infection comprises epidemiological estimates of key patient populations across 45 countries. We report the total prevalence of HBV…
The multiple sclerosis (MS) therapy market comprises more than a dozen disease-modifying therapies (DMTs) spanning a range of mechanisms of action, clinical profiles, formulations, and value…
May 2019 Stable angina is the most common clinically evident manifestation of coronary heart disease (CHD); it is present in almost half of all prevalent CHD cases. The aim of chronic medical…
No novel pharmacotherapeutics have entered the AD market in more than 15 years, despite a perennially full pipeline. However, the potential launches of the first disease-modifying therapies (DMTs)…
Market Outlook According to DRG epidemiology, more than 35 million people in the United States suffer from migraines. Despite being underutilized, migraine prophylaxis is a core treatment approach…
Obesity is a significant public health concern in the United States. The body of evidence highlighting the physical and economic impact of obesity on society is growing steadily. The most…
First-line treatment of chronic heart failure (CHF) usually involves an angiotensin-converting enzyme (ACE) inhibitor, an oral beta blocker, and an oral diuretic. The addition of a second- or third…